Name
RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial - Commentary by: Peter Fasching, MD
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL